TREM2 and Alzheimer disease: Most attractively, mutations in the Siglecs TREM2 and CD33 have been distinctly associated with the development of AD, and shown to act in opposing directions relatively to microglial activation and AD risk; alleles that inhibit TREM2 function increase AD risk, whereas alleles that inhibit CD33 function reduce such risk (Malik et al., 2013).